The following excerpt is from the company's SEC filing.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
No fee required.
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
Title of each class of securities to which transaction applies:
Aggregate number of securities to which transaction applies:
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and stat e how it was determined):
Proposed maximum aggregate value of transaction:
Total fee paid:
Fee paid previously with preliminary materials.
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
Amount Previously Paid:
Form, Schedule or Registration Statement No.:
On April 5, 2017, Innoviva, Inc. made the following statement:
It is unfortunate Glass Lewis has failed to recognize Innovivas strategy is working, the degree to which its executives play a key role in the ongoing growth of the products and the productive relationship Innoviva has with GSK. It would be a mistake to risk disrupting if not abandoning a strategy that has clearly improved financial performance and delivered value to shareholders in favor of an ill-advised cost-cutting proposal that lacks any strategy to sustain our recent growth in earnings and return of capital to investors.
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever Theravance makes a similar move, sign up!
Other recent filings from the company include the following: